AASLD: From Podium to Practice: Updates in HCV Treatment

Source: CCO Official Conference Coverage of the 2010 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs

Capsule Summaries

• Pilot Study Shows Robust Antiviral Activity With GS-9256 and Tegobuvir (GS-9190)–Based 4-Week Lead-in Regimens in Treatment-Naive Patients With Genotype 1 HCV
• After 12 Weeks of Telaprevir Treatment, PegIFN/RBV Can Be Shortened to 24 Weeks in HCV Genotype 1 Patients Achieving Extended RVR
• SPRINT-2: Boceprevir Plus PegIFN/RBV for 24 Weeks Improves SVR Rates vs PegIFN/RBV in Treatment-Naive Patients With Genotype 1 HCV
• PILLAR: TMC435 Plus PegIFN/RBV Demonstrates High Rates of RVR and EVR in Treatment-Naive Patients With Genotype 1 HCV Infection
• BMS-790052 and BMS-650032 Coadministration Associated With Undetectable HCV RNA After 12 Weeks of Therapy With or Without PegIFN/RBV in Genotype 1 HCV Null Responders
• ANA598 Improves HCV RNA Response to PegIFN/RBV in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection
• Danoprevir Added to Standard PegIFN/RBV for 12 Weeks Associated With Rapid and Potent Viral Suppression in Patients With Genotype 1 HCV Infection
• PROPEL: RG7128 Plus PegIFN alfa-2a/RBV Demonstrates High Rates of RVR and cEVR in Treatment-Naive Patients Infected With Genotype 1/4 HCV
• Vaniprevir (MK-7009) With Peginterferon alfa-2a Plus Ribavirin Produces Higher RVR Rates in Treatment-Naive Genotype 1 HCV Patients
• ADVANCE: Telaprevir Plus PegIFN/RBV Associated With Significant Increases in SVR in Treatment-Naive Patients With Genotype 1 HCV
• RESPOND-2: High SVR Rates With Boceprevir and PegIFN/RBV Combination Therapy in Patients With Genotype 1 HCV Failing Previous PegIFN/RBV
• MK-5172 Demonstrated Potent Antiviral Activity in Patients With Chronic Genotype 1 or 3 HCV Infection
• Modeling Study Results Support IL-28B Genotype Stratification in HCV Clinical Trials of PegIFN/RBV Plus Direct-Acting Antivirals
• Peginterferon Lambda Demonstrates Promising Early Virologic Response and Favorable Tolerability for the Treatment of HCV Infection
• Higher Early Virologic Response With Telaprevir Plus PegIFN/RBV vs PegIFN/RBV or Telaprevir Monotherapy but Similar Rates of SVR in Treatment-Naive Patients With Genotype 4 HCV

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

 

Source